|
|
|
|
|
|
|
|
|
|
  USA (English)
 
Mission
Quality Policy
Business Conduct
Management
Our Future
Clinical Trials
OEM Business
Disclaimer

Our Future

“From the coronary cath-lab to the operating room, from critical care to outpatient day surgery, Atrium will aggressively pursue those clinically proven product technologies which make a positive difference in the quality of care.

  Ted Karwoski
  Chief Development Officer

 

Atrium is a diversified healthcare company with excellence in balloon expandable covered stents, local drug delivery, soft tissue and hernia repair, market leading chest drainage devices, and novel vascular graft technologies. It is expected that Atrium’s diversified product portfolio will continue to provide strong company growth throughout the decade.

As the demand for newer, more efficacious medical devices and surgical procedures continue to evolve, so does the demand for expansive “evidence based” clinical trials. That’s why Atrium has collaborated with several leading physicians and clinical researchers from around the globe to help focus in on those important med-tech discoveries that can significantly improve patient outcomes.

Atrium has multiple new product developments underway and is currently conducting several multi-center clinical trials, including a landmark clinical study with its micro-porous local drug delivery balloon catheter called Clearway RX™. This patented “rapid exchange” catheter can be used to deliver medication to several remote and hard to reach anatomical locations using Atrium's advanced microporous balloon technology, including treatment of an acute coronary myocardial infarct (AMI) with a clot dissolving or anti-platelet medication, and or treatment of acute thrombus occlusions such as the femoral artery. Atrium is engineering several novel solutions for acute “thrombus management” including localized drug delivery via a micro-porous balloon catheter and future considerations for mechanical thrombus removal with a low profile thrombus extraction catheter technology.

Atrium is also aggressively pursuing late-breaking advances in barrier mesh and ventral hernia repair with its expanding family of Omega 3 coated surgical mesh products. These novel omega 3 fatty acid coated mesh technologies have demonstrated clinical improvements following surgical intervention. By combining next generation implant technologies with various Omega 3 coating platforms, it is hoped that such surgical devices will result in improved patient outcomes following surgery.

These are but a few of the exciting development projects happening at Atrium. With the dedication and determination of hundreds of talented employees, Atrium will remain focused on its mission to satisfy a global healthcare need. Whether it is a new mobile chest drain for more efficient patient convalescence following cardiac or thoracic surgery, Atrium’s challenge will be to deliver “better patient outcomes” via enhanced product performance in a number of related med-tech industries.

 



Contact an Atrium Sales Representative

US and Canada: 1-800-528-7486
Europe: +31 297 230 420
Australia/Asia: +61 2 8272 3100